Company News: GlaxoSmithKline, Eli Lilly

Share this article:

GlaxoSmithKline has announced plans to commit $1 million of its Cevarix cervical cancer vaccine to the Pink Ribbon Red Ribbon partnership over the next five years, which will afford more than 10,000 girls and women to have access to vaccination. The company has also pledged $50,000 to support the overall program's operations. The Pink Ribbon Red Ribbon partnership is an initiative led by the George W. Bush Institute, the President's Emergency Plan for AIDS Relief (PEPFAR), Susan G. Komen for the Cure and the Joint United Nations Program on HIV/AIDS (UNAIDS). Over time, this program will look to expand the availability of prevention, screening and treatment programs for cervical and breast cancer in developing countries, according to a release.

Eli Lilly and Co. has announced plans to dedicate $30 million over the next five years to a program called Lilly NCD Partnership, which will focus on finding better ways to fight diabetes in developing nations. The company also will also sponsor a conference in Washington, D.C., on Wednesday to discuss the treatment of non-communicable diseases, such as diabetes. This decision comes in conjunction with the United Nations' global efforts in bringing attention to fight the rise in diabetes, cancer and other non-communicable diseases in developing nations. For this initiative, Lilly will target its spending in Brazil, India, Mexico and South Africa, where the rates of diabetes currently run from about 5% to 10% of the populations.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.